Nick Diamantopoulos, founder of SupaG Health Pty Ltd, will introduce new garlic products at the Gilroy Garlic Festival in July, following the publication of peer-reviewed studies indicating that certain garlic varieties possess significant antiviral properties. The research, published in the Journal of Functional Foods (2024) and JSFA Reports (2026), demonstrated that specific garlic cultivars showed strong activity in laboratory studies against respiratory viruses, including SARS-CoV-2 (COVID-19) and Influenza A. The in vitro studies revealed that only a small subset of garlic varieties, regardless of growing location, exhibited meaningful antiviral activity, and that certain garlic extracts were able to impede viral entry into host cells.
“These findings fundamentally change the way we should think about garlic,” Diamantopoulos said. “For generations, garlic has been viewed as a natural remedy, however our research indicates that not all garlic is equal for health benefits, just as not all garlic is equal for nutrition and flavor. Different varieties possess different biochemical and functional properties, and in identifying these cultivars, we can open the door to entirely new categories of garlic health products.”
The research program draws on more than 30 years of collection, breeding, and analysis, involving over 300 garlic varieties sourced from around the world. Diamantopoulos believes the discoveries may represent one of the most historically significant scientific developments in the garlic industry. “The future of garlic nutraceuticals will not be commodity-based. It will be health-specific. We are moving from generic garlic products towards identified cultivars with targeted functional properties, proprietary formulations, traceable genetics and evidence-based health positioning,” he said.
SupaG Health will present its product at the Gilroy Garlic Festival, described as the nation's premier summer food event. The premium garlic supplement features a proprietary ingredient focused on specific formulations supported by peer-reviewed scientific research. The company is actively pursuing distribution partnerships, nutraceutical and pharmaceutical collaborations, retail expansion opportunities, and further product development based on its proprietary research. Throughout the festival, Diamantopoulos and the SupaGarlic team will be available to discuss the published research, commercial development plans, and opportunities for strategic partnerships, distribution, and clinical research partners.
According to the published studies, biological activity likely depends on the underlying garlic cultivar, extraction methods, formulation techniques, and processing controls. This creates opportunities to develop intellectual property around identified cultivars and proprietary formulations for the nutraceutical, functional food, and pharma sectors. “This research establishes a scientific foundation for a new premium category within the health industry. Gilroy is the ideal place to begin that conversation with the world,” Diamantopoulos said.
The scientific studies referenced were conducted in laboratory settings and do not constitute clinical evidence in humans. These statements have not been evaluated by the U.S. Food and Drug Administration, and SupaG Health products are not intended to diagnose, treat, cure, or prevent any disease. For more information, the published studies can be accessed at Journal of Functional Foods (2024) and JSFA Reports (2026).
